Bristol-Myers Squibb Co. (BMY) is in the Pharma Industry

• Sort by
• View by Content Type

• Sanofi Hit By Generic Plavix Threat in Europe

  By Ben Hirschler LONDON (Reuters) - French drugmaker Sanofi-Aventis SASY, which briefly encountered generic competition to its second-biggest product Plavix in the United States in 2006 and 2007, now faces a similar threat in Europe. Schweizerhall SWHN, a Swiss generic drug company, said...

  News items 2008-05-09

  Tags: Financial accounting, drug company, Sanofi-Aventis, Luxembourg, Germany, Europe, patent, London, Thomson Reuters Corp., intellectual property right, license agreement, stock, marketing, analyst, earnings per share, sales, U.S., intellectual property, security

• Improving Environmental Performance

  As a leading pharmaceutical company, Bristol-Myers Squibb's mission is ?to extend and enhance human life. The company's core values, as embodied in the Bristol-Myers Squibb Pledge, focus on sustaining and improving the lives of people throughout the world. We feel that our support of this document is tangible evidence of...

  White papers 2004-03-22

  Tags: Bristol-Myers Squibb Co., leader, health care

• global strategic sourcing

  Article discusses a case of Bristol-Myers that focus on how the organization plans to deliver its billion in cost savings. Bristol-Myers Squibb has been sourcing strategically since 1996. Between 1996 and 2002, the company's Glob

  White papers

  Tags: Purchasing & Procurement, Strategy, Reed Elsevier Inc., sourcing, cost savings

• Compressed Air System Renovation Project Improves Production at a Food Processing Facility

  Bristol-Myers Squibb is a diversified, worldwide health and personal care company whose main products are pharmaceuticals, consumer medicines, beauty care, nutritional supplements, and medical devices. The Evansville plant conducted an evaluation of its plant with some technical assistance from an independent consultant to determine how to best improve the system....

  Case studies

  Tags: HEALTHCARE, U.S. Department of Energy, medical device, food, health care

• Bristol-Myers Squibb

  Bristol-Myers Squibb is a Fortune 100 corporation and widely recognized as one of the leading pharmaceutical companies in the world. It needed best-of-breed portal technology to support the research efforts of its drug discovery and development teams. Verity offered the perfect antidote. Verity's advanced portal infrastructure software helps Bristol-Myers Squibb...

  Case studies

  Tags: Bristol-Myers Squibb Co., Verity Inc., patient, portal, software

Additional Resources

• Bristol-Myers Squibb to Present at Healthcare Conference

  * Will Reaffirm 3-Year 15% Compound Annual Growth Rate of Earnings Per Share * Expects to Update 2008 Earnings Guidance No Later Than End of Second Quarter NEW YORK -- Bristol-Myers Squibb Company (NYSE:BMY) will present today at the 33rd Annual Deutsche Bank Healthcare Conference. Lamberto...

  Articles 2008-05-07

• Exelixis Announces First Quarter 2008 Financial Results

  SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire-FirstCall/ -- Exelixis, Inc. today reported financial results for the first quarter ended March 31, 2008. Revenues for the quarter ended March 31, 2008 were $27.9 million, compared to $28.1 million for the comparable period in 2007. Revenues for 2008...

  Articles 2008-05-06

• Bristol-Myers Squibb to leverage ASI for Business Intelligence and Analytics

  KING OF PRUSSIA, Pa. -- Today ASI Business Solutions, Inc., the pioneers of Precision Intelligence([TM]) formally announced that Bristol-Myers Squibb (NYSE:BMY) has joined the ranks of those pharmaceutical companies who rely on ASI's solutions to optimize sales force effectiveness and increase market share. The selected combination of ASI...

  Articles 2008-05-05

• Nordic Capital Fund VII and Avista Capital Partners Agree to Acquire ConvaTec Business for approximately $4.1 Billion

  NEW YORK -- Bristol-Myers Squibb Company (NYSE:BMY) announced today it has signed a definitive agreement to sell its ConvaTec business unit to Nordic Capital Fund VII ("Nordic Capital") and Avista Capital Partners ("Avista") for $4.1 billion subject to adjustments based on ConvaTec's audited 2007 financial statements and closing working capital....

  Articles 2008-05-02

• Bristol-Myers Squibb Invites Public to Listen to Webcast of 2008 Annual Meeting

  NEW YORK, April 30 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company invites investors and the general public to listen to a webcast of its annual meeting with stockholders at 10 a.m. ET on Tuesday, May 6, 2008. In addition to the stockholder and board items to be transacted, senior executives...

  Articles 2008-04-30

• Bristol-Myers Squibb Issues $1.6 Billion of Senior Notes

  NEW YORK, April 29 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company announced today that it has agreed to sell $1.6 billion of senior unsecured notes: $600 million in aggregate principal amount of 5.450% notes due May 1, 2018 and $1 billion in aggregate principal amount of 6.125% notes due May...

  Articles 2008-04-29

• Asbury Automotive Group Names Craig T. Monaghan Incoming Senior Vice President and Chief Financial Officer

  NEW YORK, April 29 /PRNewswire-FirstCall/ -- Asbury Automotive Group, Inc. , one of the largest automotive retail and service companies in the U.S., today announced that Craig T. Monaghan has been named incoming Senior Vice President and Chief Financial Officer. Mr. Monaghan will replace J. Gordon Smith effective...

  Articles 2008-04-29

• MedImpact Study Highlights the Effects of Restricted Access on Use of Antipsychotic Drugs

  New Research Examining Compliance and Drug Benefit Designs to be Presented at ISPOR International Conference SAN DIEGO -- MedImpact researchers will present findings from an important study that highlights a connection between drug benefit designs and compliance with drug therapy among individuals suffering from schizophrenia and schizoaffective disorders....

  Articles 2008-04-29

• Fitch Rates Bristol-Myers Squibb's Senior Notes 'A+'

  CHICAGO -- Fitch Ratings has assigned an 'A+' rating to Bristol-Myers Squibb Company's (Bristol-Myers Squibb) proposed issuance of 10-year and 30-year senior unsecured notes. The senior notes are ranked pari passu with existing senior unsecured debt. Proceeds from this issuance are expected to be used for general corporate...

  Articles 2008-04-28

• HeartWare Appoints David R. Hathaway, M.D. Chief Medical Officer

  FRAMINGHAM, Mass. and SYDNEY, Australia, April 28 /PRNewswire-FirstCall/ -- HeartWare Limited today announced the appointment of David R. Hathaway, M.D. as Chief Medical Officer, reporting directly to Chief Executive Officer Doug Godshall. Dr. Hathaway has previously served as Chief Medical Officer for several drug discovery and...

  Articles 2008-04-28

• BARACLUDE® Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients

  MILAN, Italy, April 26 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company today announced new data from the E.A.R.L.Y. study (ETV-079), in which treatment of antiviral-naive adult chronic hepatitis B patients with BARACLUDER entecavir resulted in greater long-term viral load reduction than adefovir at 96 weeks -- consistent with earlier 12-week...

  Articles 2008-04-26

• Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab

  PRINCETON, N.J., April 25 /PRNewswire-FirstCall/ -- Medarex, Inc. and Bristol-Myers Squibb Company today announced that, after meeting with the U.S. Food and Drug Administration FDA, the companies will delay the Biologics License Application BLA submission for ipilimumab, an investigational immunotherapy for patients with advanced metastatic melanoma....

  Articles 2008-04-25

• Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company

  - Reports Broad-Based Net Sales Growth of 20% from Continuing Operations Driven by Strong Performance of Pharmaceutical Business - Records Pre-Tax Earnings from Continuing Operations of $1.3 Billion Representing an Increase of 51% From First Quarter 2007 - Posts First Quarter 2008 GAAP EPS from Continuing...

  Articles 2008-04-24

• Seven Summits Research Releases Comments on SBUX, CVX, AFL, BMY, and ADSK

  CHICAGO, April 24 /PRNewswire/ -- Seven Summits Research releases NewsBites on key stocks. Seven Summits Strategic Investments NewsBites are available to all investors at: http://www.go7now.com/nb/0424Y (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's Seven...

  Articles 2008-04-24

• Ex-Bristol-Myers Squibb official indicted for lying to feds

  WASHINGTON AFP — A former senior vice president of Bristol-Myers Squibb Company BMS has been indicted for lying about a patent deal involving the blood-thinning drug Plavix, justice officials said Wednesday. Andrew Bodnar faces up to five years in prison and a fine of more than 250,000 dollars...

  Articles 2008-04-23